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1.   INTRODUCTION 
      Diabetes mellitus   is a   chronic   disease    with   hyperglycemia .   The  
metabolic  dysfunction  affect  various  organs  lead  dysfunction  and  failure  .    
The   most  common type, Type-II   Diabetes Mellitus   results   from a 
combination of  genetic  and acquired factors.   Prevalence of Type-II   
Diabetes  is  increasing  globally  and  has  reached  epidemic proportion in 
many countries especially in India.
4 
The inflammatory   process    plays a   crucial   role  in the pathogenesis  
of   type 2 diabetes and   precedes the onset of the disease
8
. Vascular damage 
caused by  endothelial  cells  can be  inﬂuenced  by hyperglycaemia, increased 
free fatty acids, altered    lipoproteins, hypertension  and diabetes mellitus. 
Subclinical inﬂammation may  be associated with the increased  cardiovascular  
risk in patients with impaired glucose tolerance. 
8 
                   Neutrophil  lymphocyte  ratio   NLR  is novel   marker of  
subclinical inflammation 
7
. Many   studies    heighted    increased   NLR ratio   
with    chronic    complication   of   diabetes   both   microvascular     and   
microvascular . There   also  significant   relation  between    neutrophil  
lymphocyte ratio and glycosylated   haemoglobin  .   From India very little has 
been documented about this topic. The objective of the present study is to find 
the  relation  between     neutrophil lymphocyte ratio  and     blood  glucose 
regulation in type  2 diabetes patient   .  
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2. REVIEW OF LITERATURE 
DIABETES   MELLITUS 
Diabetes Mellitus  is   a “Group of  Metabolic   disorders   characterized  
by  chronic  hyperglycemia  associated   with alteration in carbohydrate , 
protein  and fat  metabolism   resulting  from  defects in Insulin Secretion, 
Insulin action or both”. 
The   most   common   morbidity and   mortality   predictor  is  blood 
glucose level. The American   Diabetes   Association   criteria for diagnosis of 
diabetes include  Fasting   plasma   glucose   value of greater than 126 mg/dl or 
2 hour plasma   glucose level   following   meals of   more  than 200mg/l or  
Random   plasma glucose value of greater than   200mg/ml   plus   symptom of   
diabetes   or  Hemoglobin A1c >= 6.5%. 
EPIDEMOLOGY 
According   to   the   International   Diabetes   Federation   the total  
number   of   adult   Type-II Diabetes  in  the world   was estimated as 366 
million in 2015 which was projected   to increase to 592 million by 2035
1
.   
World  diabetic   population    China   ranks   first  with   98.4 million   next     
India  with 65.1 million in 2013 . Five   Asian   countries  occupy   first  ten 
world diabetic population . The   numbers   are   estimated   to rise to  129.7  
million and   101.2 million  respectively by 2030.
4 
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DIABETES – CLASSIFICATION [23] 
I. Type 1 Diabetes mellitus ( complete cell destruction, leads to absolute 
insulin loss) 
A. Immune-mediated destruction 
B. Idiopathic aetiology 
 
II. Type 2 diabetes  mellitus (has combination of  insulin resistance with 
 Some insulin deficiency to a dominantly insulin synthesis defect with 
 insulin resistance) 
III. Other sub- types of diabetes mellitus 
A. Genetic alterations in  cell function which manifests  by mutations in: 
1. Hepatocyte  nuclear  transcription  factor(MODY TYPE 1) 
2. Glucokinase (MODY  TYPE 2) 
4 
 
3. HNF-1 (MODY 3) 
4. Insulin promoter factor-1 ( MODY 4) 
5. HNF-1 (MODY 5) 
6. NeuroD1 (MODY 6) 
7. Mitochondrial DNA 
8. Subunits  for  ATP-sensitive potassium channel 
 
B. Genetic abnormalities in insulin action 
1. Type A insulin resistance 
2. Leprechaunism 
3. Rabson-Mendenhall syndrome 
4.  Lipodystrophy syndromes 
 
C. Diseases of the exocrine pancreas – eg..pancreatitis, neoplasia, cystic 
fibrosis, hemochromatosis, fibrocalculous pancreatopathy                    
 
D. Endocrinopathies  -   includes  acromegaly, Cushing's syndrome, 
glucagonoma, pheochromocytoma, hyperthyroidism etc 
 
E. Drugs and  chemicals — pentamidine, nicotinic acid, glucocorticoids, 
thyroid hormone, diazoxide, adrenergic agonists, thiazides, phenytoin, 
interferon, protease inhibitors, clozapine. 
F.  Infections—congenital rubella, coxsackie virus,  
G. Other genetic syndromes associated with diabetes— Turner's syndrome, 
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Friedreich’s ataxia, Huntington's chorea, Laurence-Moon-Biedl syndrome, 
myotonic dystrophy, Prader-Willi syndrome,klinefelters and turners 
syndrome. 
1V   Gestational diabetes[23] 
 
 
 
 
 
 
 
6 
 
PHYSIOLOGY OF INSULIN SECRETION 
 
Risk Factors implicated in  Diabetes[17] 
 Family history of diabetes mellitus 
 People with Impaired fasting or post prandial glucose values 
 physical inactivity 
 overweight 
 Race/ethnicity 
 Hypertension  
 Low HDL cholesterol  and high  triglyceride level(greater than 250 mg) 
 History of Gestational DM or an overweight new born baby 
 
 Polycystic ovarian disease.  
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MODIFIABLE   RISK   FOR    TYPE 2   DIABETES 
OBESITY 
             One  of  the  strongest  modifiable  factor   for  diabetes is  obesity  and  
weight  gain .  BMI body mass index is  used  as  surrogate  for  obesity  
calculated by  dividing   person ‘s  weight in  kg   and  height in  meters  
square. There   is    2.75  times  increase   diabetic risk    in people  with    BMI  
of    25-27 kg  /m2   compared  to   BMI  < 22  kg/m2 .  
PHYSICAL   ACTIVITY 
Risk  of  diabetes  is found to  be inversely  proportional  to Physical 
activity   in   most  population 
3
 . Numerous  studies  shown  that   exercise  is  
related to  acute  and  long  term  improvement  in  insulin  sensitivity   and  
reduction  in   insulin   concentrations  .   
SEDENDARY   LIFESTYLE 
A    study   revealed  that in those   people  who did sedentary work like 
watching television or computer for more than 4 hours (2 to  10 hours ) had  
66% higher risk  for diabetes . 
DIETARY  FACTORS 
High   fat   diet    associated   with   obesity   and  increased  body  fat.  
Studies  investigated  the  effect of  different   subtypes  of   fat  like   saturated  
, polysaturated   ,  monosaturated   fat  and  omega 3  fatty acids on  diabetic 
risk  concluded  that beneficial effect of   higher  intake  of   PUFA  and  long  
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chain n -3 fatty acids  
3
 and   there is  deleterious  effect  due to higher  intake  
of  saturated  fat .  Risk  of  diabetes  in relation to carbohydrate  intake   was   
postulated because of  hypothesis  that   carbohydrate  ingestion    had  
immediate  challenge on  beta  cells  in comparison to  protein and fat    but   
study  result  inconclusive . The postprandial  elevation  dependent  on glucose 
absorption rate . The  glucose absorption rate  related  to many  factors like   
carbohydrate  type  and  amount of fibre. 
RISK  FACTORS   FOR   TYPE 2 DIABETES  -NONTRADITIONAL  
MODIFIABLE   
INFLAMMATION 
Though  the  main  characterstic   of  diabetes  is   insulin resistance and  
relative  insulin  deficiency,  the   underlying   mechanism   remains  unknown.   
Recently   evidence   point  out   that  inflammation   play  a  significant  role  
in   the  development  of  type 2 diabetes  and   atherosclerosis.  Many    
number  of  cross section   studies   showed    raising   Neutrophil   lymphocyte   
ratio    with    diabetes,  a marker of  subclinical   inflammation. Study   Data   
made   subclinical   inflammation   an  important  determinant of  type  2   
diabetes mellitus  . It  is  noteworthy   ,insulin  resistance is  reduced  by high 
dose  aspirin   and   improves  glucose   tolerance
 
in type 2  diabetes
3
 . 
SMOKING 
     In    Facchini  et al  study  they  compared  chronic smoker with  non 
smokers    found   significant  higher triglycerides  level and  lower  HDL 
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cholesterol level  and increased  insulin concentration  after   a 75 g  oral 
glucose tolerance test  .The mechanism  behind  insulin  resistance in smoking  
is oxidative  stress  which  cause endothelial dysfunction  .        
AETIOPATHOGENESIS  OF TYPE 2 DIABETES MELLITUS 
Genetic   factors  play  siginicant  role in type  2 diabetes .Studies  of 
identical twins  highlighted  genetic factors  as a dominant factors  in  type 2 
diabetes etiology  revealing   100%  concordance . 
The current   understanding    of type 2   DM    include   triple   
abnormalities in   the  genesis  of    hyperglycemia   include  
1.  Impaired  pancreatic   insulin  secretion  
Normal    Fasting    insulin   is  5 -15 mU/ml .  Normally  insulin 
secreted  in   pulsatile  fashion  called    ultradian   oscillations  ,which  secret 
every 90  to 120 minutes  and  exaggerated  after food   intake .The   insulin 
secretion   following   glucose   load    show biphasic   response .   First   phase 
due to   stored  insulin  in granules   which released and suppresses  hepatic  
glucose output .  This  occur  within 4 to 5 minutes  and return  to  normal 
within 10 minutes.  The  second  phase   occur due  to     rise  in glucose  level   
which   increase  peripheral  glucose uptake in  muscle and adipose  tissue 
2
.   
This    pulsatile     ultradian  oscillations  of  insulin   delivery and  first   phase  
insulin   release   lost  in   type  2  Diabetes  Mellitus.   
 
10 
 
2. Impaired   peripheral  action of  insulin: 
Numerous    studies   provide evidences   that   hyperinsulinemia   
antedates   type  2  diabetes  development .    Various   tissues  like, muscle, 
splanchnic  etc.. involved in  insulin  resistance 
3.
 
In muscle there is defect in   action   of   
1. Impaired insulin receptor  tyrokinase  activity  
2. Decreased glucose transporters 
3. Diminished  glycogen  synthase  and   pyruvate   dehydrogenase 
3.  Increased    hepatic   glucose  output   and  lipid production   
              Normally insulin  is  released  into portal  vein  and  transport   into  
liver to  suppress   hepatic  gluconeogenesis  after  glucose   ingestion .  Due   
to insulin  resistance     ,failure  of  the  liver to  perceive   signal   result in  
increased   hepatic  glucose   output  .        
In   adipose  tissues   due  to   insulin  resistance,  lipolysis  and free fatty   
acid  flux   from adipose   tissue  increased   lead  to   increased  lipid  ( VLDL , 
triglycerides  )   production in  liver  .  The  accumulation of    lipids  might  led 
to   hepatic  steatosis    and   non alcoholic   fatty  liver disease    with   
dearranged    liver   function . 
INSULIN   RESISTANCE  AS  A PRIMARY  DEFECT    
Prospective  studies  have  shown  result  that  hyperinsulinemia  and  
insulin  resistance  preceed  the  development  of  Impaired  glucose tolerance. 
11 
 
The  stage  between  normal glucose  tolerance  and  development   of  type 2 
diabetes is IGT.  Cross sectional  studies    have  shown  that  insulin  resistance   
is  inherited defect  that  intiates  the   diabetic event. . 
The  hyperglycemia to   insulin resistance  occurs in  three phases  
First  phase    -    plasma  glucose  remains  normal  despite   insulin resistance 
because  of  increased insulin  secretion  . 
Second  phase    -   As   the   insulin  resistance    progesses   there  is  impaired  
glucose  uptake  in  the    muscle   but   sufficient  insulin   produced  to   
maintain   hepatic   glucose  production  in normal  level  . So   there  is  
Postprandial  hyperglycemia    and  still   normal  fasting   blood   glucose. 
Third  phase    -   Hyperglycemia    become  severe     so   there    is  no   
longer  adequate   hyperinsulinemia     to  maintain  fasting   blood  glucose   
normal. 
The   resultant   fasting   and  postprandial   hyperglycemia    stimulate   
further beta  cell    and  produce  hyperinsulinemia   which  down  regulate  
receptor   excerbate     insulin  resistance. 
NATURAL  HISTORY OF  TYPE 2 DIABETES MELLITUS  
                 To  maintain  normal  glucose  hemostasis  there   should be  balance 
interaction  between   insulin  sensitivity   and  insulin secretion .  
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Fasting   glucose  
The   main   factor     determine   fasting  blood   glucose   is Hepatic  
glucose production  .   It   depend   on         
 Fasting   plasma   insulin  
 Hepatic  sensitivity   to insulin 
 Fasting  substrate  availability 
In  Type  2 Diabetes  there is  impaired  basal insulin  secretion  and   
decreased   hepatic  insulin sensitivity . 
Postprandial   glucose 
It    is  regulated   by   ingested  glucose  clearance ,  hepatic  glucose  
suppression  and  peripheral  glucose  clearance  . 
In Type   2   Diabetes    , there is   lack  glucagon  suppression, delayed   
& reduced insulin secretion   and   hepatic and  peripheral  resistance . 
LIPOTOXICITY
 
Adipose  tissue  considered as  an  endocrine  organ  and  it is  principle  
site  for  energy   storage   and    secretion  of  adipokines 
13
  . Adipose  tissue  
influences   insulin  action  by  release  of  free  fatty  acid and  adipose  derived  
proteins  .Adipose   derived  proteins  are pro inflammatory   peptides  and  
have  adverse   effect  on  glucose  metabolism  and  insulin  action . 
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Proinflammatory   Cytokines  
                There   is   overproduction   of   pro inflammatory   cytokines by the 
expanded      mass   of   Adipose   tissue. The   proinflammatory   cytokines   
include   interleukin IL-1, IL-18, IL-6, CRP- c reactive   protein,   restin   and   
tumour necrosis factor (TNF)
1
. The primary   source of    these    
proinflammatory    cytokines both in  the  systemic circulation as well as  
locally is  the macrophages    derived   from adipose tissue. However     it     is 
unclear  as  to how   much   the   paracrine    and endocrine effects of     these    
cytokines    lead    to insulin resistance.
1 
Adiponectin  
Adipocytes   produce an anti inflammatory cytokine exclusively called 
Adiponectin.   This   adiponectin   increases the sensitivity of insulin and it 
inhibits the  Inflammatory    process in  several  steps.  Adiponectin   inhibits    
the    gluconeogenic enzymes  and thus reduces the rate of  production of 
glucose in the liver  .   Adiponectin enhances   the transport of glucose in the 
muscles and increases the oxidation of fatty   acids     partly     because    of   
activation of    adenosine   monophosphate  kinase   .Decreased  plasma  level  
of   the   adiponectin  contributes  to  pathogenesis    to insulin  resistance  and   
type  2  DM . 
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Diagnosis 
American Diabetes Association says that any of the following can be 
used for diagnosis of diabetes: 
5 
  HbA1c or glycosylated haemoglobin test 
  FPG  -a fasting plasma glucose test 
  OGTT - an oral glucose tolerance test  
The HbA1c levels give an idea about the glucose value during the past 3 
months. It gives a fair idea how treatment is working.
18 
The haemoglobin is present inside the red blood cells. The function of 
haemoglobin is to transport oxygen to the tissues. When the red blood cells are 
constantly exposed to high level of blood glucose, the glucose enters inside the 
cells to form a bond with the haemoglobin to form glycosylated haemoglobin. 
This hba1c gives the average blood glucose control over the past 3 months. 
Hence it is necessary to check hba1c values at least twice a year. 
The A1C test results could be reported as eAG or as "average glucose," 
which directly correlates with A1C. eAG is a unit similar to self-monitor on the 
CBG machine. A1C is reported as a percent and eAG as mg/dl .
16 
eAG is not the same average glucose level as the average of values on 
the meter. This is because people with diabetes more likely check blood 
glucose when they are low (usually, in the morning and before meals), the 
average of these readings is mostly lower than eAG. 
15 
 
Fasting Blood Glucose 
It is the blood glucose values which are taken in early morning with 
fasting for at least 8 hours from previous night. 
Oral Glucose Tolerance Test (OGTT) 
It’s a test to determine how well the body metabolises glucose. Here 
blood glucose values are taken in fasting. The patient is made to drink a special 
glucose solution and blood glucose values are taken after 2 hours. 
Result 
Oral Glucose Tolerance Test 
(OGTT) 
Normal less than 140 mg/dl 
Prediabetes 140 mg/dl to 199 mg/dl 
Diabetes 200 mg/dl or higher
16 
 
Random Plasma Glucose Test 
This can be done at any time of the day. When the random plasma 
glucose values are more than 200mg/dl then it is diagnostic of diabetes 
Prediabetes: 
Prediabetes is defined as blood glucose levels which are more than 
normal but not yet high to be diagnosed as diabetes.  Both impaired fasting 
glucose and impaired glucose tolerance come under prediabetes. These people 
must be regularly followed up for they have a high chance of developing overt 
diabetes and cardiovascular complications. 
16 
 
 
 
 
COMPLICATION : 
The complications of diabetes    can be   acute   or   chronic  complication  
ACUTE   COMPLICATION 
Diabetic keto acidosis 
Hyperglycemic hyperosmolar  state 
Hypoglycemia 
Chronic Complication  
Chronic    complication   are due to the increased blood glucose for a 
long period of time.
20
 It’s the duration of diabetes which determines the 
incidence of complications.  
17 
 
           The   complications   due to   diabetes can be divided as    macrovascular 
and  microvascular. They affect multiple organ system primarily the kidneys, 
heart, eyes, brain vessels and peripheral vessels of the limbs. It causes diabetic 
nephropathy, myocardial infarction,  cerebrovascular  accidents and gangrene 
of the limbs. Moreover diabetes predisposes to hyperlipidemia and 
hypertension which increases the risk of complications. 
           Many  studies  like  Diabetes  Control  and Complications  Trial  
(DCCT)  proved  that   insulin dependent  diabetes  whose managed  with  
intensive insulin   therapy   resulted in  HbA1c  2% lower than  conventional 
insulin  and  lower incidence of complication 
12
. The   UKPDS  proved  35% 
reduction  in microvascular complication  in  each    reduction  in  HbA1C %  
1
  
The vascular complications in diabetes mellitus are mainly due to 
microangiopathy and atherosclerosis. Damage to the endothelial basement 
membrane, proliferation of endothelial cells and dysfunction of the endothelial 
cells are mainly responsible for the microangiopathy. Increased blood glucose 
causes hardening of the vessel wall and this along with increased lipids in the 
blood results in lipid deposition in atherosclerotic plaques predisposing to end 
organ damage. 
The pathophysiology involved in development of microvascular and 
macrovascular complications in diabetes is very complex. There is no clear cut 
mechanism. Increased blood glucose values for a long duration of time have 
been found to be the most important single factor causing complications. 
However not all those who have increased blood glucose develop 
18 
 
complications and sometimes even those who have very good control of blood 
glucose end up developing the complications of diabetes mellitus. 
Increased sugar affects many cell types and their extracellular matrix. 
These changes result in structural and functional alterations in the tissues.  
The cell membranes are formed mainly by the phospholipid bilayers. 
Hence alterations in lipid metabolism affect the cell membranes resulting in 
damage to the cells. The oxidation of low-density lipoprotein in 
hyperglycaemic individuals raises oxidant stress in the vessel wall. This attracts 
the monocytes and macrophages to the vessel wall were oxidized LDL results 
in alterations in cell adhesion.it also increases the release of cytokines and 
growth factors.
20
 Moreover Growth factor causes multiplication of smooth 
muscle resulting in increase in thickness of vessel wall. Further there is 
increased atherosclerotic plaque formation and microthrombi formation in 
major blood vessel .the changes in vascular permeability and endothelial cell 
dysfunction causes end organ damage. 
Sustained hyperglycaemia causes linking by sugar with proteins, lipids, 
and nucleic acids. There is increased deposition of advanced glycation end 
products in the micro blood vessels of the retina, glomerulus, and endoneurons, 
as well as the larger blood vessel walls. People who have poorly controlled 
diabetes mellitus have increased formation of advanced glycation end products. 
These advanced glycation end products cause change in the structural and 
functional change in the cells of various tissues. AGE formation on collagen 
impairs healing of damaged tissues and thus the normal homeostatic process is 
19 
 
deranged.  AGE-modified collagen forms in the walls of the large blood vessels 
and causes vessel wall thickening and narrowness of the lumen. These 
immobilize the circulating LDL, contributing to formation of atherosclerotic 
plaque. The formation of AGEs causes increase in basement membrane 
thickening in the retinal microvasculature and around the nerves and increase 
in thickness of the mesangium in the glomerulus. The end point of all these 
changes is causing narrowing of the blood vessels resulting in decreased 
perfusion to the organs. 
Formation of AGE has its effect at the cellular level also resulting in 
changes in extracellular matrix and causing alterations in cell-to-matrix and 
matrix-to-matrix interrelations. The binding of AGEs to specific cell receptors 
which have been identified on the surface of smooth-muscle cells, endothelium, 
neural cells, monocytes, and macrophages causes increased vascular 
permeability and thrombotic complications, multiplication of smooth muscle in 
vasculature, and phenotypic changes in monocytes and macrophages. This 
causes increased responsiveness of monocytes and macrophages on 
stimulation, which results in increase in the production of proinflammatory 
cytokines and associated growth factors. These cytokines and growth factors 
contribute to the chronic inflammation in the production of atherosclerotic 
lesions. They also change the wound-healing events. More production of 
inflammatory mediators causes raised tissue destruction in response to antigens 
such as the bacteria. 
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These alterations in protein and lipid metabolism, causes elevated 
plasma glucose levels which is an important feature of diabetes, which provides 
a common relation between the different diabetic complications. However, 
these metabolic changes vary among people. For example, AGEs form in both 
diabetic and non-diabetic persons, but its accumulation is more in those with 
diabetes. There are significant differences in AGE formation even within the 
diabetic population, and it is thought that this may explain the changes in the 
incidence and progression of diabetic complications
48
. 
TREATMENT 
ORAL   AGENTS 
INSULIN SECRETOGOGUES 
Sulfonylureas  
The  first  generation  sulfonylureas  are no longer in use nowadays 
because of the increased side effects  associated with these drugs.
2
  
Chlorpropamide  is an example of first   generation  sulfonylureas. 
 Second-generation agents which are more potent, have less drug 
interactions, and produce fewer side effects and hence have replaced the first 
generation. The mechanism  by which  sulfonylureas act is by acting on the 
pancreatic beta cells and causing increase in insulin secretion. This increased 
insulin secretion overcomes the resistance associated with type 2 diabetes 
mellitus and hence more amount of glucose is transported inside the cells 
thereby decreasing the blood glucose value. The sulfonylureas  depending upon  
their  varying   action  duration they are given as single or double dosage 
21 
 
daily
6
. The major adverse effect associated  with   sulfonylureas   is 
hypoglycaemia. Hence the patients who take these drugs must be educated 
properly to take adequate amount of food after taking these tablets. 
Non sulfonylurea   secretogogues  
           Repaglinide stimulates pancreatic insulin secretion. But the 
pharmacodynamic properties and mechanism of action are different from 
sulfonylureas.   Repaglinide   undergoes rapid absorption, reaches peak plasma 
levels in 30 to 60 minutes, and undergoes rapid metabolism. The drug is 
consumed along with meals and reduces the peaks of PPBS which is common 
in type 2 diabetes but to a greater degree than the sulfonylureas medications. 
These drugs are used for the treatment of  post  prandial  hyperglycaemia due 
to their rapid onset and short duration of action. These drugs can also result in 
hypoglycaemic episodes. Neteglinide  is faster  acting  than   repaglinide  and   
can  be  given  in  mild  to  moderate  liver  dysfunction 
2
. 
INSULIN   SENSITIZERS 
Biganides 
Metformin  are  biguanides and are preferred agents for obese patients. 
These drugs decrease blood glucose by decreasing the production and 
increasing the utilization . It   activate  AMP  dependent   protein  kinase . 
These drugs also inhibit the intestinal absorption of glucose. Lactic acidosis 
and megaloblastic anaemia due to vitamin b12 deficiency are the major adverse 
effects of these drugs. Biguanides increase the intestinal production of lactate 
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by anaerobic glycolysis. Metformin is the only oral agent that has been 
demonstrated to reduce the macrovascular events in type 2 DM. 
Thiazolidinedione 
The thiazolidinedione group of drugs, which includes troglitazone, 
rosiglitazone, and pioglitazone, act as agonists of nuclear receptor PPAR 
gamma which regulates transcription of genes involved in glucose and lipid 
metabolism. These drugs are used to reverse insulin resistance in type 2 DM. 
these drugs also tend to increase HDL. The adverse effect of these drugs 
includes weight gain, edema and plasma volume expansion. Therefore these 
should be avoided in CHF patients. 
Alpha – glucosidase   inhibitors  
Acarbose- complex carbohydrates are absorbed after conversion to 
simple carbohydrates by alpha  glucosidase. Inhibitors of this enzyme decrease 
carbohydrate absorption for git. Major adverse effect is flatulence due to 
fermentation of unabsorbed carbohydrates. These drugs help in restoring beta 
cell function and prevent new cases of type 2 diabetes in pre diabetes 
Dipeptidyl peptidase inhibitors 
DPPT IV  prolong  endogenous   GLP -1  action   promotes insulin  
secretion  . HbA1C  reduction  by  0.5 – 0.8%. They include  sitaglipin  
,saxagliptin  ,vildagliptin. 
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Sodium glucose co transporter  2  inhibitors   
 Sodium glucose co transporter 2 inhibitor   increase  urinary glucose 
excretion  and  thereby lower  blood glucose . They  are insulin independent.  
Adverse effect include  urinary   tract  infections .Drugs include canagliflozin  
,dapagliflozin , empagliflozin .  
 
 
 
Fig: Chart Showing The Different Treatments for  
Iabetes and its   Efficacy  
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Fig: Diagram showing site of action of anti-diabetic drugs 
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Insulin 
Insulin was discovered by Banting and Best in the year 1921. Glucose is 
the main stimulus for the release of insulin from the beta cells of the pancreas. 
Glucose stimulates GLUT-2 and inhibits ATP sensitive k+ channels. The 
actions of insulin include stimulation of entry of glucose in muscle and fat, 
inhibition of glycogenolysis and gluconeogenesis and increasing glycolysis and 
glycogenesis. By all the above mentioned mechanisms insulin decreases the 
blood glucose levels. It also inhibits lipolysis and favours deposition of 
triglyceride. It caused increased synthesis of proteins and thus overall has an 
anabolic action. 
The human insulin is prepared by recombinant DNA technology and has 
rapid absorption and shorter duration of action. Recently ultra-short acting and 
ultra-long acting preparations have also been developed. All insulin 
preparations are supplied at neutral pH of 7.2 to 7.4 except glargine which is 
supplied at pH of 4. Hence it is important that glargine should not be mixed 
with any other preparation of insulin.  
All insulin preparations are given by subcutaneous route only. Only 
regular insulin can be given by intra venous route. The factors which affect the 
absorption of insulin include the type and site of injection, the depth of 
injection and subcutaneous blood flow.  
The most common complication of an insulin therapy is hypoglycaemia. 
This can be treated with intravenous glucose. Some people suffer from 
hypoglycaemic unawareness. Usually when the blood glucose levels drop less 
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than 60mg/dl the symptoms of hypoglycaemia becomes apparent. However in 
patients suffering from hypoglycaemic unawareness there is no symptoms till 
blood glucose values plummets to 40mg/dl. The patient becomes unconscious 
and often this condition is life threatening. Then at the site of injection it can 
cause lipodystrophy. Allergic reactions and sodium and water retention have 
found to occur.  
The indications of insulin therapy include all cases of insulin dependent 
diabetes mellitus. Among non insulin dependent diabetes mellitus insulin is 
indicated when glucose levels are not controlled with oral hypoglycaemic 
agents, in pregnancy and in complications like diabetic ketoacidosis and 
hyperosmolar coma in in stressful conditions like surgery and infections. 
           Exogenous insulin  usage gives  a   profile similar  to the non-diabetic 
individual, with a continuous availability of insulin available which is 
enhanced by increase in availability after each meal
6
. No single insulin 
preparation is available which are able to achieve this goal with one or two 
injections daily.  Insulin preparation combinations are available which are 
taken three or more times daily or using a subcutaneous infusion pump more 
approximate to the ideal conditions, but even in conditional regimes, blood 
glucose levels can remain unstable. 
           Ultralente insulin also called as "peakless" insulin is the longest acting 
insulin.it has a very slow action onset of action and it peaks very minimum and 
action is for a longer duration. It action resembles the basal metabolic insulin 
6
. 
The intermediate-acting insulin (lente and neutral protamine Hagedorn [NPH]) 
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have their peak action several hours after injection. Peak activity occurs 
between 4 to 10 hours after injection. Therefore a patient who is using 
intermediate-acting insulin in the early morning will have peak plasma insulin 
levels during lunch hours. Regular insulin is shorter acting, with its onset being 
around about 30 minutes through 1 hour post injection and  peaks at 2 -3 hours. 
Lispro  insulin, a rapid acting insulin, due to its rapid absorption, will become 
active about 15 minutes post injection, and peaks at ½ to 11/2 hours. Rapid- 
and short-acting insulin are usually taken just before or during meals. Thus, 
regular insulin when taken before breakfast will peak at midmorning; when 
taken before lunch, will peak at mid-afternoon. 
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Prevention 
             Studies  have shown that by doing lifestyle modifications we 
cansubstantially reduce the risk of developing type two diabetes mellitus and 
the chances of developing cardiovascular diseases. In diabetes prevention 
program about 3234 obese subjects with impaired glucose tolerance or 
impaired fasting glucose were put into three groups. One group with intensive 
lifestyle changes through exercise and low fat diet, second group with 
metformin with information about exercise and diet and third group on placebo 
with information on exercise and diet. After three years of follow up it was 
found out that less number of patients in the intensive lifestyle group developed 
diabetes . 
Daily regular exercise, healthy food habits, having an apt weight plays a 
major role in preventing diabetes and the complications. These also help in 
reducing the blood pressure and heart disease among type 2 diabetic patients. 
NEUTROPHIL- LYMPHOCYTE RATIO 
Normally     there are 4000-11000 WBCS/ micro litre in the human 
blood. Of these granulocytes are the most numerous. Young granulocytes have 
horse shoe shaped nuclei that become  multilobed as the cells grow older. Most 
of them contain   neutrophilic  granules. 
NEUTROPHILS 
Neutrophils  have   cytoplasmic   granules that contain biologically 
active substances involved in inflammatory reactions. The average half- life of 
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a neutrophil in the circulation is 6 hours. They are attracted to the endothelial 
surface by selectins and they roll along it. Neutrophil adhesion molecules of the 
integrin family helps them to get bound to selectins. They insinuate themselves 
through the walls of the capillaries by a process known as diapedesis. Many of 
those that leave the circulation enter the GI tract and are lost from the body. 
Neutrophilic   granules contain various proteases and in addition they 
also contain enzymes such as NADPH  oxidase, catalase and 
myeloperoxidases. NADPH oxidase is associated with a sharp increase in 
oxygen intake and metabolism in the neutrophil, what we call as the 
“Respiratory burst” and this reaction generates plenty of free O-radicals. The  
myeloperoxidase  catalyses the conversion of Halides and cyanides to their 
corresponding acid forms. These acids  inturn are potent oxidants by 
themselves. 
In addition to myeloperoxidase and NADPH oxidase neutrophil granules 
also contain an elastase and two metalloproteinases. 
The total body neutrophils can be divided into circulating pool (CGP) 
and marginating granulocyte pool. In these two pools, the cells are equal size 
and they are in constant equilibrium. MGP represents the neutrophils involved 
in adhesion and rolling along the endothelial cells in post capillary venules and 
they are not found in blood obtained by venepuncture. So the neutrophil 
content actually represents about half of the total no of neutrophils in the 
vascular compartment. 
31 
 
LYMPHOCYTES 
Lymphocytes are motile non phagocytic cells. There are many 
subpopulations of lymphocytes which interact with each other and with cells of 
the monocyte macrophage system. They help in maintaining both humoral and 
cell mediated immunity. Proliferating lymphocytes are enriched with enhanced 
levels of enzyme n-terminal deoxyribonucleic acid transferase. It is found in 
immature lymphoid cells in the bone marrow and thymocytes, but not in 
mature lymphocytes. Adenosine de aminase is present in large amounts in T-
lymphocytes and it is necessary for their immune function. 
INFLAMMATION 
Inflammation is naturally a protective mechanism against invasion of 
microbes and toxins. The inflammatory response consists of 2 main 
components- a vascular reaction and a cellular reaction. Both the reactions are 
mediated by chemical factors that are derived from plasma proteins or cells 
produced as a result of inflammatory response. 
Chronic inflammation is of prolonged duration in which active 
inflammation, tissue destruction and repair are proceeding simultaneously. 
Atheroscleorosis and vascular disease are chronic inflammatory processes of 
the arterial wall induced partly by endogenous toxic plasma lipid components. 
Morphological features of chronic inflammation 
 
 Mononuclear cell infiltration 
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 Tissue destruction 
 Healing by connective tissue replacement 
 New blood vessel formation by elaboration of vascular endothelial 
growth factor and other angiogenic factors. 
 Fibrosis 
 
Most of  these elements of chronic inflammation are found in the 
pathogenesis  of  complications   of  diabetes. 
NLR IN SUBCLINICAL INFLAMMATION 
High Neutrophil lymphocyte ratio is a marker of subclinical 
inflammation in many disease states of the vascular system.  NLR reflects the 
systemic inflammatory response   that   accompanies   chronic disease   but 
might also be influenced by systemic infections, atherosclerosis, hypertension, 
chronic renal disease and diabetes. 
Subclinical vascular inflammation    measured by derived NLR is linked 
with traditional   risk factors of   chronic diseases   such as smoking,   obesity, 
hypertension and elevated levels of triglycerides. 
MECHANISMS 
Endothelial dysfunction secondary to cellular response of blood 
components heralds the onset of inflammation. Endothelial dysfunction leads to 
impaired production of nitric oxide and prostacylins. This leads to the depletion 
of anti-atherogenic, antithrombotic and vasodilator properties of the vascular 
endothelium. 
                   The normal d-NLR is < 2.0 in control population. 
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DIABETES   AND   INFLAMMATION  
           Type 2 diabetes is a   prothrombotic, pro atherosclerotic and pro 
inflammatory   condition with high association for cardiovascular morbidity 
Diabetes Mellitus has been reported to the associated with acute phase 
response. In type-2 diabetes sialic acid, alpha-1 acid glycoprotein, c-reactive 
protein, amyloid and interleukin-6 are increased
3
. Also in parallel leukocyte 
count is elevated significantly than other markers indicating ongoing 
subclinical vascular inflammation. 
Prospective  population  based   European Prospective  Investigation  
into Cancer and  Nutrition  (EPIC)- Postsdam  study     examined  type 2  
diabetes  and  the  role of  central  inflammatory  cytokines ( interleukin IL -6 , 
IL-1beta  and   tumor necrosis factor ). This  study  concluded  pathogenesis  of  
diabetes  involve  subclinical  immune activation  . 
DIABETES AND  NEUTROPHIL  LYMPHOCYTE   RATIO 
NLR  is   novel marker in determining  inflammation .It  includes  two 
markers   active nonspecific  meditors   ,neutrophil  and  lymphocyte  
productive  component  of  inflammation .
6 
In   type  2   diabetes  ,there    have   been   shown  defective   expression  
of  interleukin -2 receptors  led to   decresed  proliferation of   lymphocyte   .So   
the  present   studies  showed  increased   neutrophil  count  and  decresed   
lymphocyte  count  in  unregulated   diabetes  .  Based  on  this  studies  proved   
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increased   NLR  in  unregulated   diabetes    and   in  relation  in   
complications  of   type  2   diabetes . 
NEUTROPHIL   LYMPHOCYTE   RATIO  AND   MALIGNANCY  
           Many   studies   proved    role   of   high   NLR   in prognosis   of   solid  
tumors 
43
  . Mechanisms   involved   in   high   NLR   in  malignancy  are   
1. Inflammation  
2. Cytokine production   
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3. AIMS  AND  OBJECTIVE 
 
 To   study   neutrophil   lymphocyte   ratio  and  blood  glucose  
regulation  in   type  2  diabetes.  
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4. MATERIALS   AND  METHOD 
PLACE OF STUDY  
                  Stanley   Medical   College   and    Hospital, Chennai  
                   Department   of   General  Medicine, OPD, Medical wards  
Study population  
                    100  
Study design  
                    Prospective   and   observational   Study  
ETHICAL COMMITTEE APPROVAL  
                    Ethical   committee   approval   was   obtained   for   the   study   
OPERATIONAL   DEFINITION 
CASE   DEFINITION  
NEUTROPHIL   LYMPHOCYTE   RATIO  
Calculated   by   dividing   the number   of     neutrophils    by number   
of    lymphocytes , usually   from   peripheral  blood sample. 
The normal    NLR is < 2.0 in control population. 
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Blood glucose regulation   include   fasting blood glucose  ,postprandial 
blood glucose, HbA1c.  
PATIENT SELECTION  
Inclusion criteria  
1. Patients  with  type 2  diabetes mellitus  included    Newly diagnosed   
diabetes and   know  diabetic patient on  oral   antidiabetic  agents  and 
insulin . 
2. Age 30  years  to   70  years 
Exclusion criteria  
1) Patients takings  statins, asprin, thiazolidinediones,   
2)  Patients with acute infections  
3) Patients with chronic inflammatory conditions like inflammatory bowel 
disease, osteoarthritis, rheumatoid arthritis, gout, bronchial asthma and 
chronic  hepatits   
4) Patients with acute myocardial infarction , cerebral infarction  
5) Patients with chronic kidney disease. 
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METHOLOGY 
•  Patients aged above 30 years presenting to the Medicine out-patient 
service and those admitted to the medical wards at Stanley medical 
college hospital Chennai  were included in the present study. 
 
• The data were recorded from each subject with an in-person interview 
by administering a specific questionnaire. 
 
• Anthropometric measures noted. 
 
• In all the patients,  automated  blood  cell  counter is  used   to determine  
total WBC, neutrophil and lymphocyte levels   and   high  performance 
liquid chromatography  for  HbA1c. 
 
•  Peripheral venous blood sample was to be drawn in the morning after 8 
- 10 hours of fasting, to measure  venous plasma glucose, serum total 
cholesterol, serum high density lipoprotein (HDL) cholesterol, and 
serum triglyceride levels. 
 
• PPBS  taken  2 hour after food. 
 
• Plasma triglycerides, total cholesterol and HDL-cholesterol were to be 
measured by enzymatic colorimetric  assay  using  autoanalyser   
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Measurement of HbA1c 
Technique 
Cation   exchange  high  performance liquid chromatography. 
System 
The Biorad   D10 haemoglobin  Testing System.
38 
HB1AC 
Method :  Bio Rad HPLC  
Normal : 4 to 6% 
Good Control : 6 to 7% 
Fair Control : 7 to 8% 
Poor Control : > 8% 
ESTIMATION OF  BLOOD  GLUCOSE 
Method 
        Glucose   oxidase   method    
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HUMAN SUBJECT PROTECTION  
The full protocol along with draft questionnaire and Informed consent 
will be kept in Institutional ethical Committee and approval will be obtained.   
INFORMED CONSENT  
Consent form will be written in both English and Tamil and consent will 
be obtained from the participant, confidentiality will be maintained 
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5. RESULTS   AND   DISCUSSIONS 
Groups 
Groups Definition Number 
NLR < 2 Neutrophil-Lymphocyte 
Ratio less than 2 
41 
NLR > 2 Neutrophil-Lymphocyte 
Ratio greater than 2 
59 
 
Null Hypothesis 
Null Hypothesis : H0  Neutrophil-Lymphocyte Ratio 
greater than 2 equal in effect 
Neutrophil-Lymphocyte Ratio less 
than 2 
Alternate Hypothesis : H1  Neutrophil-Lymphocyte Ratio 
greater than 2 hazardous in effect 
Neutrophil-Lymphocyte Ratio less 
than 2 
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Data Analysis 
 
 Descriptive statistics was done for all data and were reported in 
terms of mean values and percentages. Suitable statistical tests of 
comparison were done. Continuous variables were analysed with the 
unpaired t test.. Categorical variables were analysed with the Chi-Square 
Test and Fisher Exact Test. Statistical significance was taken as P < 0.05. 
The data was analysed using SPSS version 16 and Microsoft Excel 2007.  
  
43 
 
1 
8 
11 
14 
7 
0 
8 
15 
21 
15 
0
5
10
15
20
25
≤ 30 years 31-40 years 41-50 years 51-60 years 61-70 years
N
u
m
b
e
r 
o
f 
P
at
ie
n
ts
 
Age Distribution 
NLR < 2 NLR > 2
AGE 
 
  
1, 1% 
16, 16% 
26, 26% 
35, 35% 
22, 22% 
Age Distribution 
≤ 30 years 
31-40 years
41-50 years
51-60 years
61-70 years
44 
 
 
Age 
Distribution 
NLR < 
2 
% NLR > 2 % Combined % 
≤ 30 years 1 2.44 0 0.00 1 1.00 
31-40 years 8 19.51 8 13.56 16 16.00 
41-50 years 11 26.83 15 25.42 26 26.00 
51-60 years 14 34.15 21 35.59 35 35.00 
61-70 years 7 17.07 15 25.42 22 22.00 
Total 41 100 59 100 100 100 
 
 
Age Distribution NLR < 2 NLR > 2 Combined 
N 41 59 100 
Mean 49.51 53.80 52.04 
SD 10.78 10.27 10.64 
P value 
Unpaired t Test 
0.0571 
 
Among the study patients, there was no statistically significant 
difference in relation to age distribution between NLR < 2 group (mean=49.51, 
SD=10.78) and NLR > 2 group (mean=53.80, SD=10.27) with a p value of 
<0.05 as per unpaired t test. Therefore we fail to reject the null hypothesis that 
there is no difference in age distribution between the study groups. 
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Gender 
Status 
NLR < 2 % NLR > 2 % Combined % 
Male 22 53.66 24 40.68 46 46.00 
Female 19 46.34 35 59.32 54 54.00 
Total 41 100 59 100 100 100 
P value 
Chi Squared Test 
0.2002 
 
Among the study patients, there was no statistically significant 
difference in relation to gender status between NLR < 2 group (majority are 
males – 53.66%) and NLR > 2 group (majority are females – 59.32%) with a p 
value of <0.05 as per chi squared test. Therefore we fail to reject the null 
hypothesis that there is no difference in gender status between the study 
groups. 
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BMI 
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BMI Distribution 
NLR < 
2 
% NLR > 2 % Combined % 
Underweight  
(≤ 18.49) 
0 0.00 0 0.00 0 0.00 
Normal 
 (18.50 to 24.99) 
18 43.90 9 15.25 27 27.00 
Overweight 
 (25 to 29.99) 
18 43.90 31 52.54 49 49.00 
Obese (≥ 30) 5 12.20 19 32.20 24 24.00 
Total 41 100 59 100 100 100 
 
BMI Distribution NLR < 2 NLR > 2 Combined 
N 41 59 100 
Mean 26.24 29.08 27.9144 
SD 3.68 4.16 4.19 
P value 
Unpaired t Test 
0.0007 
 
 
Among the study patients, there was a statistically significant difference 
in relation to BMI distribution between NLR < 2 group (mean=26.24, 
SD=3.68) and NLR > 2 group (mean=29.08, SD=4.16) with a p value of <0.05 
as per unpaired t test. Therefore we fail to reject the null hypothesis that there is 
no difference in BMI distribution between the study groups. 
Discussion  
The mean BMI was significantly less in NLR < 2 group compared to NLR > 2  
group by a mean difference of 2.84  (10% lower). This difference is significant 
with a p-value of 0.0007 as per unpaired t test.  
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Fasting 
Blood Sugar 
NLR < 2 % NLR > 2 % Combined % 
≤ 100 mg/dL 7 17.07 2 3.39 9 9.00 
101 -150 
mg/dL 
23 56.10 24 40.68 47 47.00 
151-200 
mg/dL 
11 26.83 27 45.76 38 38.00 
> 200 mg/dL 0 0.00 6 10.17 6 6.00 
Total 41 100 59 100 100 100 
 
Fasting Blood 
Sugar 
NLR < 2 NLR > 2 Combined 
N 41 59 100 
Mean 133.83 156.64 147.29 
SD 27.14 34.17 33.30 
P value 
Unpaired t Test 
0.0006 
 
 
Among the study patients, there was a statistically significant difference 
in relation to fasting blood sugar distribution between NLR < 2 group 
(mean=133.83, SD=27.14) and NLR > 2 group (mean=156.64, SD=34.17) with 
a p value of <0.05 as per unpaired t test. Therefore we fail to reject the null 
hypothesis that there is no difference in fasting blood sugar distribution 
between the study groups. 
Discussion  
The mean FBS was significantly less in NLR < 2 group compared to NLR > 2  
group by a mean difference of 22.81 mg/dl  (15% lower). This difference is 
significant with a p-value of 0.0006 as per unpaired t test.  
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Post 
Prandial 
Blood Sugar 
NLR < 
2 
% NLR > 2 % Combined % 
≤ 150 mg/dl 11 26.83 8 13.56 19 19.00 
151-200 
mg/dl 
7 17.07 18 30.51 25 25.00 
201-250 
mg/dl 
18 43.90 13 22.03 31 31.00 
251-300 
mg/dl 
5 12.20 11 18.64 16 16.00 
> 300 mg/dl 0 0.00 9 15.25 9 9.00 
Total 41 100 59 100 100 100 
 
 
Post Prandial 
Blood Sugar 
NLR < 2 NLR > 2 Combined 
N 41 59 100 
Mean 195.12 228.61 214.88 
SD 45.03 67.43 61.29 
P value 
Unpaired t Test 
0.0066 
 
Among the study patients, there was a statistically significant difference 
in relation to post prandial blood sugar distribution between NLR < 2 group 
(mean=195.12, SD=45.03) and NLR > 2 group (mean=228.61, SD=67.43) with 
a p value of <0.05 as per unpaired t test. Therefore we fail to reject the null 
hypothesis that there is no difference in post prandial blood sugar distribution 
between the study groups. 
Discussion  
The mean PPBS was significantly less in NLR < 2 group compared to 
NLR > 2  group by a mean difference of 33.49 mg/dl  (15% lower). This 
difference is significant with a p-value of 0.0066 as per unpaired t test.  
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HbA1c NLR < 2 % NLR > 2 % Combined % 
≤ 5 % 0 0.00 1 1.69 1 1.00 
5.1-7 % 14 34.15 7 11.86 21 21.00 
7.1-9 % 23 56.10 27 45.76 50 50.00 
9.1-11 % 1 2.44 7 11.86 8 8.00 
> 11 % 3 7.32 17 28.81 20 20.00 
Total 41 100 59 100 100 100 
 
HbA1c NLR < 2 NLR > 2 Combined 
N 41 59 100 
Mean 7.71 9.65 8.854 
SD 1.75 2.98 2.71 
P value  
Unpaired t Test 
0.0003 
 
Among the study patients, there was a statistically significant difference 
in relation to Glycated hemoglobin distribution between NLR < 2 group 
(mean=7.71, SD=1.75) and NLR > 2 group (mean=9.65, SD=2.98) with a p 
value of <0.05 as per unpaired t test. Therefore we fail to reject the null 
hypothesis that there is no difference in Glycated hemoglobin distribution 
between the study groups. 
Discussion  
The mean HbA1c was significantly less in NLR < 2 group compared to NLR > 
2  group by a mean difference of 1.94%  (20% lower). This difference is 
significant with a p-value of 0.0003 as per unpaired t test.  
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Duration of 
Diabetes 
NLR < 2 % NLR > 2 % Combined % 
≤ 5 years 19 46.34 15 25.42 34 34.00 
6 - 10 years 20 48.78 27 45.76 47 47.00 
11 - 15 years 2 4.88 15 25.42 17 17.00 
16 - 20 years 0 0.00 2 3.39 2 2.00 
Total 41 100 59 100 100 100 
 
Duration of 
Diabetes 
NLR < 2 NLR > 2 Combined 
N 41 59 100 
Mean 6.00 7.93 7.14 
SD 2.88 3.68 3.49 
P value 
Unpaired t Test 
0.0059 
 
Among the study patients, there was a statistically significant difference 
in relation to duration of diabetes distribution between NLR < 2 group 
(mean=6.00, SD=2.88) and NLR > 2 group (mean=7.93, SD=3.68) with a p 
value of <0.05 as per unpaired t test. Therefore we fail to reject the null 
hypothesis that there is no difference in duration of diabetes distribution 
between the study groups. 
Discussion  
The mean duration of diabetes was significantly shorter in NLR < 2 
group compared to NLR > 2 group by a mean difference of 1.93 years  (24% 
shorter). This difference is significant with a p-value of 0.0059 as per unpaired 
t test.  
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Hypertension NLR < 2 % NLR > 2 % Combined % 
Yes 28 68.29 34 57.63 62 62.00 
No 13 31.71 25 42.37 38 38.00 
Total 41 100 59 100 100 100 
P value 
Chi Squared Test 
0.2798 
 
Among the study patients, there was no statistically significant 
difference in relation to hypertension status between NLR < 2 group (majority 
are hypertensives – 68.29%) and NLR > 2 group (majority are hypertensives– 
57.63%) with a p value of <0.05 as per chi squared test. Therefore we fail to 
reject the null hypothesis that there is no difference in hypertension status 
between the study groups. 
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ABDOMINAL CIRCUMFERENCE 
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Abdominal 
Circumference 
NLR < 2 % NLR > 2 % Combined % 
Normal 23 56.10 15 25.42 38 38.00 
Abnormal 18 43.90 44 74.58 62 62.00 
Total 41 100 59 100 100 100 
P value 
Chi Squared Test 
0.0019 
 
Among the study patients, there was statistically significant difference in 
relation to abdominal circumference status between NLR < 2 group (majority 
are normal AC – 56.10%) and NLR > 2 group (majority are abnormal AC – 
74.58%) with a p value of <0.05 as per unpaired t test. Therefore we fail to 
reject the null hypothesis that there is no difference in abdominal 
circumference status between the study groups. 
Discussion  
The incidence of abnormal abdominal circumference was significantly 
less in NLR < 2 group compared to NLR > 2 group by a percentage difference 
of 30.67%  (41% less). This difference is significant with a p-value of 0.0019 
as per chi squared test.  
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Triglycerides NLR < 2 % NLR > 2 % Combined % 
Normal 12 29.27 14 23.73 26 26.00 
Elevated 29 70.73 45 76.27 74 74.00 
Total 41 100 59 100 100 100 
P value 
Chi Squared Test 
0.5345 
 
Among the study patients, there was no statistically significant 
difference in relation to triglycerides status between NLR < 2 group (majority 
have elevated TGL – 70.73%) and NLR > 2 group (majority have elevated 
TGL – 76.27%) with a p value of <0.05 as per chi squared test. Therefore we 
fail to reject the null hypothesis that there is no difference in triglycerides status 
between the study groups. 
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ELEVATED TRIGLYCERIDES 
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Elevated 
Triglycerides 
NLR < 2 % NLR > 2 % Combined % 
≤ 150 mg/dl 0 0.00 1 2.22 1 1.35 
151-200 mg/dl 23 79.31 23 51.11 46 62.16 
201-250 mg/dl 4 13.79 15 33.33 19 25.68 
251-300 mg/dl 2 6.90 5 11.11 7 9.46 
> 300 mg/dl 0 0.00 1 2.22 1 1.35 
Total 29 100 45 100 74 100 
  
Elevated Triglycerides NLR < 2 NLR > 2 Combined 
N 29 45 74 
Mean 196.93 208.16 203.7568 
SD 29.96 43.67 39.04 
P value 
Unpaired t Test 
0.2298 
  
Among the study patients elevated triglycerides, there was no 
statistically significant difference NLR < 2 group (mean=196.93, SD=29.69) 
and NLR > 2 group (mean=208.16, SD=43.67) with a p value of <0.05 as per 
unpaired t test. Therefore we fail to reject the null hypothesis that there is no 
difference in elevated triglycerides distribution in the study patients. 
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HDL CHOLESTEROL 
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HDL Cholesterol NLR < 2 % NLR > 2 % Combined % 
Normal 21 51.22 25 42.37 46 46.00 
Low 20 48.78 34 57.63 54 54.00 
Total 41 100 59 100 100 100 
P value 
Chi Squared Test 
0.3827 
 
Among the study patients, there was no statistically significant 
difference in relation to HDL cholesterol status between NLR < 2 group 
(majority have normal HDL cholesterol – 51.22%) and NLR > 2 group 
(majority low HDL cholesterol – 57.63%) with a p value of <0.05 as per chi 
squared test. Therefore we fail to reject the null hypothesis that there is no 
difference in HDL cholesterol status between the study groups. 
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LOW HDL CHOLESTEROL 
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Low 
HDL Cholesterol NLR < 2 % NLR > 2 % Combined % 
21-30 mg/dl 5 26.32 6 17.65 11 20.75 
31-40 mg/dl 14 73.68 22 64.71 36 67.92 
41-50 mg/dl 0 0.00 6 17.65 6 11.32 
Total 19 100 34 100 53 100 
  
 
Low HDL Cholesterol NLR < 2 NLR > 2 Combined 
N 19 34 53 
Mean 33.47 35.76 34.94 
SD 3.29 5.51 4.92 
P value 
Unpaired t Test 
0.1049 
  
 
Among the study patients low HDL cholesterol, there was no 
statistically significant difference NLR < 2 group (mean=33.47, SD=3.29) and 
NLR > 2 group (mean=35.76, SD=5.51) with a p value of <0.05 as per 
unpaired t test. Therefore we fail to reject the null hypothesis that there is no 
difference in low HDL cholesterol distribution in the study patients. 
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EXERCISE 
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Exercise NLR < 2 % NLR > 2 % Combined % 
Yes 23 56.10 25 42.37 48 48.00 
No 18 43.90 34 57.63 52 52.00 
Total 41 100 59 100 100 100 
P value 
Chi Squared Test 
0.1767 
 
Among the study patients, there was no statistically significant 
difference in relation to exercise status between NLR < 2 group (majority do 
exercise – 56.10%) and NLR > 2 group (majority don’t do exercise – 57.63%) 
with a p value of <0.05 as per chi squared test. Therefore we fail to reject the 
null hypothesis that there is no difference in exercise status between the study 
groups. 
  
71 
 
NON VEGETARIAN DIET 
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Non 
Vegetarian 
Diet 
NLR < 2 % NLR > 2 % Combined % 
Yes 27 65.85 42 71.19 69 69.00 
No 14 34.15 17 28.81 31 31.00 
Total 41 100 59 100 100 100 
P value 
Chi Squared Test 
0.5706 
 
Among the study patients, there was no statistically significant 
difference in relation to non vegetarian diet status between NLR < 2 group 
(majority eat NV diet – 65.85%) and NLR > 2 group (majority eat NV diet – 
71.19%) with a p value of <0.05 as per chi squared test. Therefore we fail to 
reject the null hypothesis that there is no difference in non vegetarian diet 
status  between the study groups. 
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CONCLUSION 
The following were the conclusion of this study  
 The association between the study groups and age distribution is 
considered to   be not statistically significant.  
 The association between the study groups and gender distribution is 
considered   to be not statistically significant 
 In  this  study we can safely conclude that significant increase in BMI  is 
associated  with  increase in NLR ratio in our study subjects especially 
in the overweight and obese category. In other words overweight and 
obesity was 1.10 times more in patients with NLR > 2 compared to 
those with NLR < 2.  
 In this study we can safely conclude that significant increase in Fasting 
blood sugar is associated with  increase in NLR ratio in our study 
subjects especially in > 150 mg/dl category. In other words high fasting 
blood sugar was 1.17 times more in patients with NLR > 2 compared to 
those with NLR < 2.  
 In this study we can safely conclude that significant increase in post 
prandial blood sugar is associated with increase in NLR ratio in our 
study subjects especially in > 250 mg/dl category. In other words high 
post prandial blood sugar was 1.17 times more in patients with NLR > 2 
compared to those with NLR < 2.  
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 In this study we can safely conclude that significant increase 
Glycosylated hemoglobin is associated with   increase in NLR ratio in 
our study subjects especially in > 9% category. In other words high  
Glycosylated hemoglobin was 1.25 times more in patients with NLR > 2 
compared to those with NLR < 2.  
 In this study we can safely conclude that significant increase duration of 
diabetes is associated  with  increase in NLR ratio in our study subjects 
especially in > 10 years category. In other words duration of diabetes 
was 1.32 times more in patients with NLR > 2 compared to those with 
NLR < 2.  
 The association between the study groups and hypertension is 
considered   to be not statistically significant. 
 In this study we can safely conclude that significant increase abdominal 
circumference is   associated with  increase in NLR ratio in our study 
subjects.  
 In other words abnormal abdominal circumference was 1.70 times more 
in patients with NLR > 2 compared to those with NLR < 2.  
 There is   no statistical  significant    between  study  groups  and    TGL  
and  HDL  levels 
 Exercising   status   is found to have a negative correlation with NLR . 
 There   is  no difference in non vegetarian diet status  between  the study 
groups. 
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SUMMARY 
This   study   undertaken   to   establish   Neutrophil  Lymphocyte Ratio 
which can be easily calculated from a simple peripheral blood count and  
therefore, is much simpler and cheaper than measuring more sophisticated 
inflammatory cytokines in patients with diabetes.   
            Thus   there is positive correlation of   NLR   with   blood  glucose ,  
HBA1c duration of diabetes ,  BMI and   abnormal abdominal diameter   
proved.  Increase  Glycosylated   haemoglobin   is associated with   increase in 
NLR ratio in our study subjects especially in > 9% category. 
So with simple  Neutrophil  Lymphocyte Ratio test,  if steps to reduce 
inflammation are taken early in people with diabetes the morbidity and 
mortality can be reduced.  
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                                                  PROFORMA 
 
NAME:                                             
AGE: 1. 30-40yrs   2. 40-60yrs  3. >60yrs           SEX: 1.M   2.F 
 
 
LOCALITY:                                                        CONTACT NO: 
 
 
 
COMPLAINTS             : 
 
PAST H/O 
DIABETES:     1. Yes  2. No  If yes specify________ 
HYPERTENSION             1. Yes  2. No  If yes specify________ 
RENAL FAILURE             1. Yes  2. No  If yes specify________ 
AUTOIMMUNE DISORDER 1. Yes  2. No  If yes specify________ 
CARDIAC ILLNESS  1. Yes  2. No  If yes specify________ 
STROKE     1. Yes  2. No  If yes specify________ 
CONNECTIVE TISSUES  1. Yes  2. No  If yes specify________  
 DISORDER 
 INFLAMMATORY BOWEL 1. Yes        2. No  If yes specify_________ 
DISEASE 
OSTEOARTHRITIES  1. Yes        2. No  If yes specify_________ 
RHEUMATOID ARTHRITIS 1. Yes        2. No  If yes specify_________ 
GOUT    1. Yes        2. No  If yes specify_________   
BRONCHIAL ASTHMA  1. Yes        2. No  If yes specify_________ 
OTHERS            _______________________ 
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H/O CHRONIC DRUG INTAKE: 
 
H/O OF ANY RECENT FEVER : 1. YES  2 .NO 
 
PERSONAL H/O 
 
FOOD  :                       1.veg  2.Non veg 
 
SMOKING               :  1. Yes   2. No 
 
 
ALCOHOL INTAKE: 1. Yes 2. No 
 
EXERCISE OF ATLEAST 30 MINS FOR 5 DAYS A WEEK: 1. Yes 2. No 
 
VITALS-  
 
 BP:                                      PR:                          RR:                        
TEMPERATURE-     
 
   BMI:                          ABD DIAMETER: 
 
SYSTEMIC EXAMINATION-  
 
CVS:                                                           RS:                             PA: 
 
CNS: 
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INVESTIGATIONS 
CBC  :                                            NEUTROPHIL LYMPHOCYTE RATIO 
 
RFT : 
 
FBS : 
 
PPBS: 
 
HBA1C: 
 
LIPID  PROFILE  : 
 
HDL-  
 
TRIGLYCERIDES-   
 
ECG  FINDINGS-    
 
COMMENT:  
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GOVT.STANLEY MEDICAL COLLEGE, CHENNAI- 600 001 
 
INFORMED CONSENT 
 
DISSERTATION TOPIC: “NEUTROPHIL    LYMPHOCYTE   RATIO   
AND  BLOOD  GLUCOSE  REGULATION  IN  TYPE  2  DIABETES “ 
 
PLACE OF STUDY: GOVT. STANLEY MEDICAL COLLEGE, CHENNAI 
 
NAME AND ADDRESS OF PATIENT: 
 
 I, _____________________ have been informed about the details of the study 
in my own language. 
 
I have completely understood the details of the study. 
 
I am aware of the possible risks and benefits, while taking part in the study. 
 
I understand that I can withdraw from the study at any point of time and even 
then, I will continue to receive the medical treatment as usual. 
 
I understand that I will not get any payment for taking part in this study. 
 
I will not object if the results of this study are getting published in any medical 
journal, provided my personal identity is not revealed. 
 
I know what I am supposed to do by taking part in this study and I assure that I 
would extend my full co-operation for this study. 
 
Name and Address of the Volunteer:  
 
Signature/Thumb impression of the Volunteer 
 
Date: 
 
Witnesses: 
(Signature, Name & Address) 
 
Date: 
Name and signature of investigator: 
88 
 
GOVT.STANLEY MEDICAL COLLEGE, CHENNAI- 600 001 
 
INFORMED CONSENT 
 
DISSERTATION TOPIC: “NEUTROPHIL    LYMPHOCYTE   RATIO   AND  BLOOD  GLUCOSE  
REGULATION  IN  TYPE  2  DIABETES “ 
 
 நான்இந்தஆராய்ச்சியில்விவரங்களைமுற்றிலும்புாிந்துககாண்டேன்.  
ஆய்வில்பங்குஎடுத்துடபாது, 
சாத்தியமானஅபாயங்கள்மற்றும்பயன்களைபற்றிநான்அறிந்துள்டைன். 
நான்எந்தகவாருடவளையிலும்ஆய்வில்இருந்துதிரும்பமுடியும், அதன்பின்னர், 
நான்வழக்கம்டபால்மருத்துவசிகிச்ளசகபறமுடியும்என்றுபுாிந்துககாள்கிடறன். 
நான்ஆய்வில்பங்குஎடுத்துபணம்எளதயும்கபறமுடியாதுஎன்றுஅறிந்துள்டைன்.  
இந்தஆய்வின்முடிவுகள்எந்தகமடிக்கல்ஜர்னலில்கவைியிேப்பேஇருந்தால்நான்எதிர்க்
கவில்ளை, என்தனிப்பட்ேஅளேயாைத்ளதகவைிப்படுத்தப்பட்டுஇருக்ககூோது. 
நான்இந்தஆய்வில்பங்ககடுப்பதன்மூைம்நான்என்னகசய்யடபாகிடறன்என்று
கதாியும். 
நான்இந்தஆய்வில்என்முழுஒத்துளழப்ளபயும்ககாடுப்டபன்என்றுஉறுதியைிக்கிடறன். 
 
தன்னார்வைர்       சாட்சி  
கபயர்மற்றும்முகவாி     கபயர்மற்றும்முகவாி 
ளககயாப்பம்  /விரல்டரளக:     ளககயாப்பம் / விரல்டரளக: 
 
 
ஆராய்ச்சியாைராக 
ளககயாப்பம்மற்றும்டததி 
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ETHICAL COMMITTEE APPROVAL 
 
MASTER CHART 
 
SL 
NO 
AGE SEX BMI 
DIABETIC HYPERTENSION 
AB 
DIAME 
TGL HDL EXERICSE NV NLR>2 
FBS PPBS HBAIC DURATION Y OR N Y OR N Y OR N Y OR N Y OR N Y OR N Y OR N 
               1 56 F 31.8 152 204 8.4 4 N Y- 100 Y-274 Y-47 N Y Y 
2 69 M 25.7 164 184 7.2 8 Y N Y-170 N N Y Y 
3 35 M 29.2 114 124 6.1 2 N Y-98 Y-160 Y-35 Y Y N 
4 48 F 27.4 245 299 10.7 8 Y Y-90 Y-210 Y-44 N Y Y 
5 41 M 32.4 120 147 7.6 10 Y Y-96 Y-196 N Y N N 
6 37 F 26.9 149 198 8.9 1 N Y-88 Y-240 Y-31 N Y Y 
7 55 M 29.4 184 201 9.8 11 Y Y-94 N Y-34 N Y Y 
8 69 F 38.4 199 304 14.5 15 N Y-109 Y-284 Y-29 Y Y Y 
9 45 F 22.4 154 199 8.6 12 Y N Y-274 N Y Y N 
10 52 F 34.7 120 138 7.8 8 N Y-114 Y-198 Y-31 N Y Y 
11 45 F 29.4 124 134 7.2 6 Y Y-95 Y-274 Y-28 Y Y Y 
12 52 M 28.4 110 134 6 4 Y Y-99 Y-221 N Y Y N 
13 39 F 34.7 85 110 5.8 7 N Y-119 Y-246 Y- 39 N Y Y 
14 35 M 28.4 178 201 8.4 2 Y Y-99 Y-274 N Y N N 
15 45 M 22.7 112 144 6.5 6 Y N Y-245 N Y Y N 
16 56 M 31 154 199 8.7 7 N Y-101 Y-214 Y-34 N Y Y 
17 68 F 28.7 199 245 11.2 12 Y Y-93 Y- 188 Y-44 N Y Y 
18 32 M 24.45 114 178 8.8 1 Y N Y-172 Y-36 Y Y N 
19 45 M 21.6 152 184 9.4 3 Y N Y-184 N Y N Y 
20 54 M 19.32 99 124 5.1 9 Y N Y-199 Y-35 N Y N 
21 46 F 28.47 147 320 17.4 5 Y Y-98 Y-245 N N Y Y 
SL 
NO 
AGE SEX BMI 
DIABETIC HYPERTENSION 
AB 
DIAME 
TGL HDL EXERICSE NV NLR>2 
FBS PPBS HBAIC DURATION Y OR N Y OR N Y OR N Y OR N Y OR N Y OR N Y OR N 
22 56 M 27.45 158 198 8.4 2 Y Y-94 Y-178 Y-44 N Y Y 
23 38 F 33.4 132 148 6.4 3 N Y=119 Y-298 N N Y Y 
24 44 F 38.4 123 164 7.3 8 N Y-110 Y-210 Y-39 N Y Y 
25 54 F 27.1 245 336 13.9 11 Y Y-99 Y-343 Y-44 N Y Y 
26 65 F 28.4 147 204 12.4 17 Y Y=96 N N N Y Y 
27 62 F 32.6 124 178 9.4 5 Y Y-110 N N N Y N 
28 47 M 29.4 164 245 12.4 7 Y Y-94 Y-202 N Y Y Y 
29 65 F 33.1 110 138 7.5 12 Y Y-101 Y-189 N N Y Y 
30 40 M 21.7 145 187 8.5 4 Y N Y-175 Y-35 N N N 
31 58 F 28.6 135 154 7.1 18 Y Y-91 Y=170 N N Y Y 
32 51 M 20.4 125 138 7.3 5 Y N Y-198 N N Y N 
33 60 F 33.4 110 136 6.4 4 Y Y-101 N N N Y Y 
34 63 F 21.4 94 125 5.9 9 Y N N Y-39 N Y N 
35 54 M 27.9 212 384 14.8 5 Y Y-94 172 Y-35 Y Y Y 
36 65 F 25.3 100 202 12 8 Y N Y-200 N N Y N 
37 61 M 37.4 99 121 7.1 12 Y Y-110 Y-241 N Y Y Y 
38 48 M 33.8 144 198 12.4 7 Y Y-98 N Y-35 Y Y Y 
39 54 F 28.4 154 178 8.6 5 N Y-90 Y-219 Y-39 N Y Y 
40 36 F 24.6 167 254 12.8 3 N Y-95 Y-250 Y-35 N Y Y 
41 54 M 24.9 189 269 13.9 8 Y N Y-244 Y-27 Y Y N 
42 45 F 29.1 178 289 16.8 8 Y Y-91 Y-186 Y-37 N N Y 
43 56 M 24.6 110 154 8.4 11 Y N Y-187 N Y Y Y 
44 49 F 33.3 212 298 13.6 6 Y Y-101 Y-198 Y-34 N Y Y 
45 67 F 22.8 147 245 12.1 12 Y N Y-166 N N Y Y 
46 27 F 31.4 145 210 11.6 1 N Y-118 Y-177 Y-39 N Y N 
SL 
NO 
AGE SEX BMI 
DIABETIC HYPERTENSION 
AB 
DIAME 
TGL HDL EXERICSE NV NLR>2 
FBS PPBS HBAIC DURATION Y OR N Y OR N Y OR N Y OR N Y OR N Y OR N Y OR N 
47 35 M 25.5 158 249 9.4 4 Y N Y-167 Y-32 N Y Y 
48 45 F 26.8 145 239 8.9 7 Y N Y-189 Y-36 N Y N 
49 57 F 29.1 141 297 14.2 11 Y Y-95 Y-168 N N Y Y 
50 48 F 36.5 178 299 15.4 7 N Y-104 Y-298 Y-35 Y Y Y 
51 55 M 21.5 114 138 6.3 8 N N N N Y Y N 
52 31 F 28.4 145 214 7.1 4 N Y-89 N N N Y N 
53 36 M 29.4 110 176 8.1 7 Y N Y-214 N N N Y 
54 47 M 27.4 141 204 7.2 8 Y Y-99 N Y-34 Y Y N 
55 62 F 22.8 124 210 7.6 5 N Y-101 Y-188 N N N N 
56 58 F 24.5 154 187 8.4 6 Y Y-98 Y-140 Y-27 Y Y Y 
57 49 M 28.4 140 224 7.9 9 Y N N N Y Y N 
58 65 F 27.5 154 198 8.4 8 N Y-98 Y-198 Y-37 N N Y 
59 54 M 28.4 145 202 7.9 8 Y N N N Y Y N 
60 58 M 28.7 178 242 8.4 11 N Y-104 Y-178 Y-34 Y N Y 
61 69 F 23.4 164 187 7.4 13 N N Y-169 N N N Y 
62 54 M 22.4 144 188 6.6 7 Y N N Y-29 Y Y N 
63 47 M 25.8 148 204 6.9 8 N Y-91 N N Y Y Y 
64 35 F 22.4 110 138 5.8 3 Y N Y-161 N Y N N 
65 67 M 26.3 148 202 7.9 8 Y N Y-198 Y-32 Y N N 
66 58 F 24.4 198 304 9.6 7 Y Y-110 N N Y N Y 
67 32 F 22.4 110 178 7.2 1 N Y-96 Y-187 Y-36 N Y N 
68 49 M 29.4 168 254 8.6 8 N N Y-178 N Y N N 
69 51 M 34.5 204 398 15.9 14 N Y-108 N N Y N Y 
70 63 F 24.6 158 245 7.9 7 Y N Y-178 Y Y N N 
71 55 F 33.4 145 189 8.4 11 N Y-99 Y-165 N N N Y 
SL 
NO 
AGE SEX BMI 
DIABETIC HYPERTENSION 
AB 
DIAME 
TGL HDL EXERICSE NV NLR>2 
FBS PPBS HBAIC DURATION Y OR N Y OR N Y OR N Y OR N Y OR N Y OR N Y OR N 
72 47 F 27.1 157 245 7.9 9 N Y-104 N Y-38 Y Y Y 
73 36 M 31.2 142 289 7.6 6 Y Y-115 N N Y Y Y 
74 58 F 24.6 164 221 8.3 8 Y N Y-158 Y-34 N Y N 
75 67 F 27.5 155 259 7.9 11 N N N N N Y N 
76 55 M 33.6 198 224 8.1 8 Y Y-108 Y-187 Y-32 Y N N 
77 59 M 29.7 185 287 9.6 9 N N Y-184 Y-35 Y N Y 
78 68 F 34.8 224 324 11.8 10 N Y-98 N N Y N Y 
79 35 F 26.5 140 199 8.5 2 Y N Y-202 N Y N Y 
80 60 M 28.4 164 254 7.8 9 Y N Y-187 Y-32 N N N 
81 34 F 24.8 98 124 5.6 3 N N N N Y N N 
82 59 M 28.7 165 212 8.4 11 N Y-94 Y-224 Y-39 Y N Y 
83 69 M 25.9 135 189 7.2 12 N N N N Y N Y 
84 48 F 22.7 95 129 5.9 5 Y N Y-187 N Y N N 
85 44 F 27.9 110 138 6.2 7 Y Y-87 N Y-37 Y N Y 
86 69 M 28.5 165 250 8.6 7 Y Y-116 Y-190 Y-30 N Y Y 
87 59 M 29 145 226 7.5 5 N Y-100 N N Y Y N 
88 51 F 32 90 170 6.5 2 N Y-110 Y-200 Y-35 N Y N 
89 47 F 25 127 256 8 3 Y N Y-160 Y-45 Y Y y 
90 67 M 19.45 187 310 9 6 N N Y-163 N N Y Y 
91 58 F 22.6 151 214 6.5 8 Y N N Y-25 N N y 
92 53 M 28 100 269 7 4 Y Y-100 Y-182 y -30 Y Y N 
93 49 M 26.8 130 279 10 7 N N N y-35 N Y y 
94 50 F 29.5 156 231 8 3 N Y-96 Y-177 N N N N 
95 68 M 31 180 267 7 8 Y Y -128 Y-210 Y-36 Y N Y 
96 46 M 29 152 248 6 4 y y-100 y-198 N N N N 
SL 
NO 
AGE SEX BMI 
DIABETIC HYPERTENSION 
AB 
DIAME 
TGL HDL EXERICSE NV NLR>2 
FBS PPBS HBAIC DURATION Y OR N Y OR N Y OR N Y OR N Y OR N Y OR N Y OR N 
97 59 F 27.5 139 230 6 7 N Y-116 Y-221 Y-30 N Y N 
98 65 M 30 120 200 5 5 Y Y-96 Y-180 Y-28 Y Y Y 
99 46 F 23 116 219 9 8 Y Y-88 N Y-30 Y Y N 
100 55 F 28.5 171 335 12 5 N N Y-221 N N Y Y 
 
KEY   TO   MASTER   CHART 
M                           MALE 
 F                            FEMALE 
 Y                           YES  
N                            NO 
BMI                        BODY   MASS   INDEX   
FBS                        FASTING   BLOOD   SUGAR 
PPBS                      POSTPRANDIAL   BLOOD   SUGAR 
HBA1C                 GLYCOSYLATED   HEMOGLOBIN 
NV                          NONVEG  
AB DIAMETER    ABDOMNIAL DIAMETER  
TGL                        TRIGLYCERIDES  
HDL                        HIGH DENSITY LIPOPROTEIN 
NLR                         NEUTROPHIL LYMPHOCYTE  RATIO  
 
